• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

口服铁螯合剂1,2 - 二甲基 - 3 - 羟基吡啶 - 4 - 酮(L1)的长期试验。II. 临床观察。

Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). II. Clinical observations.

作者信息

Bartlett A N, Hoffbrand A V, Kontoghiorghes G J

机构信息

Department of Haematology, Royal Free Hospital, School of Medicine, London.

出版信息

Br J Haematol. 1990 Oct;76(2):301-4. doi: 10.1111/j.1365-2141.1990.tb07888.x.

DOI:10.1111/j.1365-2141.1990.tb07888.x
PMID:2094334
Abstract

1,2-Dimethyl-3-hydroxypyrid-4-one (L1) has been given daily for 1-15 months to 13 transfusion dependent iron loaded patients. No significant change occurred in liver, renal or cardiac function, ECG and radionucleotide angiocardiogram, in audiometry tests and in visual function and electrical retinography. No skin rashes, gastrointestinal symptoms and no neurological changes that could be detected clinically were observed. Two of the patients died of their underlying diseases. One patient had severe cardiac abnormalities before receiving L1 and died of congestive heart failure with infections 5 weeks after stopping a 2-month course of L1. The other, a patient with myelodysplasia suffered recurring infections due to progression of the disease. Joint and muscle pains occurred in five patients. In two these disappeared despite continuing the drug; another patient developed swollen ankle joints which gradually resolved on stopping L1 therapy; a patient with underlying osteoarthritis complained of mild pain and stiffness in her knees which remained intermittent both on and off the drug while in the fifth patient peripheral small joint swelling and pain present before starting L1 improved with L1 therapy. One patient, with Blackfan Diamond anaemia, developed a Lw red cell antibody 6 months after commencing L1. This disappeared on stopping the drug and did not reappear. She then developed severe agranulocytosis and thrombocytopenia 6 weeks after recommencing L1 after 3 months discontinuation of the drug. No other patient showed a change in granulocyte or platelet count.

摘要

已对13名依赖输血的铁过载患者每日给予1,2 - 二甲基 - 3 - 羟基吡啶 - 4 - 酮(L1),持续1至15个月。肝脏、肾脏或心脏功能、心电图、放射性核素血管造影、听力测试、视觉功能及视网膜电图均无显著变化。未观察到皮疹、胃肠道症状以及临床可检测到的神经变化。两名患者死于基础疾病。一名患者在接受L1之前有严重心脏异常,在停止为期2个月的L1疗程5周后死于充血性心力衰竭伴感染。另一名患有骨髓发育异常的患者因疾病进展反复感染。五名患者出现关节和肌肉疼痛。其中两名患者尽管继续用药疼痛仍消失;另一名患者出现踝关节肿胀,在停止L1治疗后逐渐消退;一名患有原发性骨关节炎的患者抱怨双膝轻度疼痛和僵硬,用药和停药时均为间歇性发作;第五名患者在开始L1治疗前存在的外周小关节肿胀和疼痛经L1治疗后有所改善。一名患有先天性纯红细胞再生障碍性贫血的患者在开始使用L1 6个月后产生了Lw红细胞抗体。停药后该抗体消失且未再次出现。在停药3个月后重新开始使用L1 6周后,她出现了严重的粒细胞缺乏症和血小板减少症。其他患者均未出现粒细胞或血小板计数变化。

相似文献

1
Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). II. Clinical observations.口服铁螯合剂1,2 - 二甲基 - 3 - 羟基吡啶 - 4 - 酮(L1)的长期试验。II. 临床观察。
Br J Haematol. 1990 Oct;76(2):301-4. doi: 10.1111/j.1365-2141.1990.tb07888.x.
2
Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies.口服铁螯合剂1,2 - 二甲基 - 3 - 羟基吡啶 - 4 - 酮(L1)的长期试验。I. 铁螯合与代谢研究。
Br J Haematol. 1990 Oct;76(2):295-300. doi: 10.1111/j.1365-2141.1990.tb07887.x.
3
Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major.口服铁螯合剂1,2 - 二甲基 - 3 - 羟基吡啶 - 4 - 酮(L1)治疗重型地中海贫血的疗效及可能的不良反应
Blood. 1992 Aug 1;80(3):593-9.
4
Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial.口服铁螯合剂去铁酮(L1)对输血性铁过载的长期治疗:一项荷兰多中心试验。
Ann Hematol. 1996 Nov;73(5):247-52. doi: 10.1007/s002770050236.
5
Oral iron chelation therapy with deferiprone. Monitoring of biochemical, drug and iron excretion changes.去铁酮口服铁螯合疗法。生化、药物及铁排泄变化监测。
Arzneimittelforschung. 1995 Jan;45(1):65-9.
6
Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial.口服铁螯合剂L1用于依赖输血的地中海贫血的疗效和安全性长期评估:印度试验
Br J Haematol. 1992 Oct;82(2):460-6. doi: 10.1111/j.1365-2141.1992.tb06445.x.
7
Deferiprone-associated myelotoxicity.去铁酮相关的骨髓毒性。
Eur J Haematol. 1994 Nov;53(5):298-301. doi: 10.1111/j.1600-0609.1994.tb01323.x.
8
Efficacy and safety of 1-2, dimethyl-3-hydroxypyrid-4-one (L1) as an oral iron chelator in patients of beta thalassaemia major with iron overload.1-2,二甲基-3-羟基吡啶-4-酮(L1)作为口服铁螯合剂用于重度β地中海贫血铁过载患者的疗效和安全性。
J Assoc Physicians India. 1991 Sep;39(9):669-72.
9
Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine.接受口服铁螯合剂1,2 - 二甲基 - 3 - 羟基吡啶 - 4 - 酮或去铁胺治疗的铁过载患者的锌浓度。
J Clin Pathol. 1994 Jul;47(7):657-60. doi: 10.1136/jcp.47.7.657.
10
Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease.口服铁螯合剂1,2 - 二甲基 - 3 - 羟基吡啶 - 4 - 酮(L1)在镰状细胞病铁过载患者中的铁平衡及剂量反应研究
Blood. 1994 Apr 15;83(8):2329-33.

引用本文的文献

1
Application of Fuzzy AHP for Medication Decision Making in Iron-Chelating Medications for Thalassemia.模糊层次分析法在重型地中海贫血铁螯合剂用药决策中的应用
Pharmacy (Basel). 2025 Jun 15;13(3):86. doi: 10.3390/pharmacy13030086.
2
The Role of Iron Metabolism in Sepsis-associated Encephalopathy: a Potential Target.铁代谢在脓毒症相关性脑病中的作用:一个潜在的靶点。
Mol Neurobiol. 2024 Jul;61(7):4677-4690. doi: 10.1007/s12035-023-03870-2. Epub 2023 Dec 19.
3
Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.
去铁酮治疗地中海贫血及其他病症铁过载的获益与风险:与去铁胺的流行病学及治疗学方面比较
Drug Saf. 2003;26(8):553-84. doi: 10.2165/00002018-200326080-00003.
4
Stroke in children with sickle cell anaemia: aetiology and treatment.镰状细胞贫血患儿的中风:病因与治疗
Paediatr Drugs. 2001;3(6):421-32. doi: 10.2165/00128072-200103060-00003.
5
Deferiprone (L1) induced conformation change of hemoglobin: A fluorescence and CD spectroscopic study.
Mol Cell Biochem. 2000 Jan;204(1-2):17-20. doi: 10.1023/a:1007049701572.
6
Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.去铁酮:对其在重型β地中海贫血及其他依赖输血疾病的铁过载中临床潜力的综述
Drugs. 1999 Sep;58(3):553-78. doi: 10.2165/00003495-199958030-00021.
7
Pharmaceutical analysis of the oral iron chelator deferiprone (DMHP,L1).口服铁螯合剂去铁酮(DMHP,L1)的药物分析。
Pharm World Sci. 1996 Aug;18(4):142-7. doi: 10.1007/BF00717730.
8
Oral iron chelation: a review with special emphasis on Indian work on deferiprone (L1).口服铁螯合作用:一篇特别强调印度关于去铁酮(L1)研究工作的综述。
Indian J Pediatr. 1993 Jul-Aug;60(4):509-16. doi: 10.1007/BF02751427.
9
Oral iron chelation is here.口服铁螯合疗法出现了。
BMJ. 1991 Nov 23;303(6813):1279-80. doi: 10.1136/bmj.303.6813.1279.
10
Bone marrow transplantation for thalassaemia major.重型地中海贫血的骨髓移植
J Clin Pathol. 1992 Jul;45(7):553-5. doi: 10.1136/jcp.45.7.553.